Drug-Loaded Silver Nanoparticles—A Tool for Delivery of a Mebeverine Precursor in Inflammatory Bowel Diseases Treatment

Author:

Todorova Mina1ORCID,Milusheva Miglena12ORCID,Kaynarova Lidia3ORCID,Georgieva Deyana3ORCID,Delchev Vassil4,Simeonova Stanislava56,Pilicheva Bissera56ORCID,Nikolova Stoyanka1ORCID

Affiliation:

1. Department of Organic Chemistry, Faculty of Chemistry, University of Plovdiv, 4000 Plovdiv, Bulgaria

2. Department of Bioorganic Chemistry, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria

3. Department of Analytical Chemistry and Computer Chemistry, Faculty of Chemistry, University of Plovdiv, 4000 Plovdiv, Bulgaria

4. Department of Physical Chemistry, Faculty of Chemistry, University of Plovdiv, 4000 Plovdiv, Bulgaria

5. Department of Pharmaceutical Sciences, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria

6. Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria

Abstract

Chronic, multifactorial illnesses of the gastrointestinal tract include inflammatory bowel diseases. One of the greatest methods for regulated medicine administration in a particular region of inflammation is the nanoparticle system. Silver nanoparticles (Ag NPs) have been utilized as drug delivery systems in the pharmaceutical industry. The goal of the current study is to synthesize drug-loaded Ag NPs using a previously described 3-methyl-1-phenylbutan-2-amine, as a mebeverine precursor (MP). Methods: A green, galactose-assisted method for the rapid synthesis and stabilization of Ag NPs as a drug-delivery system is presented. Galactose was used as a reducing and capping agent forming a thin layer encasing the nanoparticles. Results: The structure, size distribution, zeta potential, surface charge, and the role of the capping agent of drug-loaded Ag NPs were discussed. The drug release of the MP-loaded Ag NPs was also investigated. The Ag NPs indicated a very good drug release between 80 and 85%. Based on the preliminary results, Ag NPs might be a promising medication delivery system for MP and a useful treatment option for inflammatory bowel disease. Therefore, future research into the potential medical applications of the produced Ag NPs is necessary.

Funder

Bulgarian Ministry of Education and Science

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Reference107 articles.

1. Overcoming therapeutic obstacles in inflammatory bowel diseases: A comprehensive review on novel drug delivery strategies;Talaei;Eur. J. Pharm. Sci.,2013

2. New oral delivery systems for treatment of inflammatory bowel disease;Friend;Adv. Drug Deliv. Rev.,2005

3. Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose–response efficacy;Vong;J. Control. Release,2015

4. Makhlouf, A.S.H., and Abu-Thabit, N.Y. (2019). Biomaterials, Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications, Woodhead Publishing.

5. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment;Wang;J. Control. Release,2022

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3